編者按

　深圳改革開放40多年來飛速發展，創造出令世界刮目相看的偉大奇蹟。今日深圳，就是中華民族實現歷史偉大變革和中華民族偉大復興的一個縮影與見證。本欄目通過港澳台僑同胞、國際友人講述他們在深圳學習、工作、生活、創業的經歷和感受，展現敢闖敢試、開放包容、務實尚法、追求卓越的深圳氣質和宜居宜業宜遊的深圳魅力。在建設中國特色社會主義先行示範區的歷史性機遇下，深圳正以「改革不停頓、開放不止步」的奮進態勢開啟新征程，並以此向中國共產黨百年華誕獻禮。

   Editor's Note

　Over the past 40 years of reform and opening up, Shenzhen has developed rapidly, creating a great miracle that makes the world look at it with new eyes. Shenzhen today is the epitome and witness of the significant historical change and rejuvenation of the Chinese nation. Through the sharing of compatriots from Hong Kong, Macao, and Taiwan areas of China and the sharing of international friends, this column tells about their experiences and feelings of studying, working, living and starting a business in Shenzhen. It shows the Shenzhen temperament of daring to venture, openness and inclusiveness, being pragmatic and law-abiding, pursuing excellence, and Shenzhen’s charm of being suitable for living, business and tourism. Under the historic opportunity of building the first pilot demonstration area of socialism with Chinese characteristics, Shenzhen is starting a new journey with the momentum of "reform does not stop, opening up does not stop", and as a tribute to the centenary of the CPC.

　「坪山對於我們是一個理想的選擇，不僅有貼心的創業環境，還有充滿活力的創新生態，這裏的生物企業相當於馬薩諸塞州波士頓都市區劍橋市生物企業的數量，那裏已經是世界上醫藥公司最集中的領域，坪山是代表未來生物醫藥發展的區域。」深圳市華先醫藥科技有限公司副總裁費安傑對選擇在坪山創業充滿自豪感。

　費安傑從小在新西蘭長大，從懷卡托大學畢業後前往澳大利亞攻讀國立大學化學專業博士。博士畢業後，費安傑順利進入了全球頂尖的生物醫藥公司葛蘭素史克工作。7年中，他從最基礎的研究員開始做起，後來擔任過基金項目經理、高級研究員等，在創新藥研發、綠色創新工藝開發及產業化、大型項目管理乃至GMP生產方面積累了大量經驗。憑藉集團提供的豐厚資源支持以及自身積累的行業經驗，費安傑工作起來如魚得水。但他始終對外面的世界感到好奇，希望走出「舒適區」，在一個更廣闊的空間更大限度地發揮自身價值、挑戰自我。

　選擇來到中國，是巧合也是選擇。費安傑與中國結緣始於2003年，出於工作需要，他曾多次來中國考察，對中國的發展機遇、國人的勤勞品質和良好的教育水平印象深刻。隨後，在好友葉偉平博士的邀請下，費安傑便順理成章來到中國，與好友一起創立了深圳市華先醫藥科技有限公司。作為聯合創始人之一，費安傑先後擔任公司研發、製造、國際業務等部門負責人，目前主要負責公司海外市場發展業務，為公司尋找客戶，面對美國、歐洲、韓國、日本等四大主要市場進行公司推廣。

　隨着公司規模的不斷擴大，原本的場地已不能滿足生產和發展需要，在朋友推薦下，費安傑決定到坪山看看。坪山所擁有的行業領先的生物醫藥產業集群、充分的產業園區實驗室空間以及優惠的租賃條件，令費安傑當即決定將新的研究實驗室設立在坪山的深圳國家生物產業基地。對於坪山的生活配套，費安傑用「people-friendly（對人友好）」來形容：現代化的建築與自然公園完美融合，在周圍生活的市民們有地方休閒、放鬆，這令企業招納人才也變得相對容易。而對於費安傑自己來說，這裏的生活也好不愜意，在這裏，他不僅收穫了事業上的成功，更組建起了幸福的家庭。費安傑的妻子是中國人，兩個孩子也在中國出生，在中國接受教育。

　2020年1月22日，深圳市人民政府辦公廳印發了《深圳市促進生物醫藥產業集聚發展指導意見及相關配套文件》（1+3文件），明確在全市打造「一核多中心」生物醫藥特色發展格局。文件中提到的「核」，就是以坪山區生物醫藥產業集聚發展主園區為核心，加快推進坪山生物醫藥科技產業城建設。

　對於未來，費安傑希望有更多的企業能到坪山發展，有更多的基礎研究和產學研合作項目來到坪山。對於整個行業走向，他預測未來AI的應用將進一步提高實驗成功率，且會在新藥研發特別是新藥的臨床試驗中起到重要作用。

　Andrew T. Phillis: success in career, harvest happiness

　--Vice President of Shenzhen Hwagen Pharmaceutical Co., Ltd.

　"Pingshan District of Shenzhen is an ideal choice for us. It not only has a caring entrepreneurial environment, but also has a dynamic innovation ecology. The number of biological enterprises here is equivalent to that of Cambridge in the Boston metropolitan area, Massachusetts, the most concentrated field of pharmaceutical companies in the world. Pingshan represents the future development of biomedicine." Andrew T. Phillis, the Vice President of Shenzhen Hwagen Pharmaceutical Co., Ltd., is full of pride in choosing to start a business in Pingshan.

　Andrew T. Phillis grew up in New Zealand. After graduating from the University of Waikato, he studied for a Ph.D. in Chemistry at the Australian National University (ANU). After graduating from the ANU, he successfully entered GlaxoSmithKline (GSK), the world's leading biomedical company. In the seven years at GSK, he started as a junior researcher, and later served as a fund project manager and senior researcher. He has accumulated a lot of experience in innovative medicine research and development, green innovation process development and industrialization, large-scale project management, and GMP production. With the rich resources provided by the group and his own experience, Andrew T. Phillis works like a duck to water. However, he is always curious about the outside world, hoping to go out of the "comfort zone" to maximize his value and challenge himself in a broader space.

　Coming to China is both a coincidence and a choice. Andrew T. Phillis's affinity with China began in 2003 when he visited China many times for work purposes and was impressed by the development opportunities, the diligence of the Chinese, and the excellent education level. Then, at the invitation of his friend Dr. Ye Weiping, Andrew T. Phillis came to China as a matter of course and founded Shenzhen Hwagen Pharmaceutical Co., Ltd. together with his friends. As one of the co-founders, Andrew T. Phillis has served as the head of the company's R&D, manufacturing, and international business departments and is currently responsible for the company's overseas market development business, finding customers for the company and promoting the company in four major markets: America, Europe, Korea, and Japan.

　With the continuous expansion of the company's scale, the original site can no longer meet the needs of production and development. Recommended by friends, Andrew T. Phillis decided to visit Pingshan. Due to Pingshan's leading biomedical industry cluster, sufficient laboratory space in the industrial park, and favorable leasing conditions, Andrew T. Phillis immediately decided to set up a new research laboratory in Pingshan's Shenzhen National Biological Industry Base. For the life-supporting facilities in Pingshan, Andrew T. Phillis describes it as "people-friendly": the perfect integration of modern architecture and natural park allow the citizens living around to have a place to relax, which makes it relatively easy for enterprises to recruit talents. For himself, living here is also very pleasant. In Pingshan, Andrew T. Phillis not only gained success in his career but also built a happy family. His wife is Chinese, and his two children were born and educated in China.

　On January 22, 2020, the General Office of Shenzhen Municipal People's Government issued the Guiding Opinions and Related Supporting Documents of Shenzhen on Promoting the Development of Biomedical Industry Cluster (1+3 documents), which clearly defined the biomedical development pattern of "one core and multi-center". The "core" mentioned in the document means accelerating the establishment of the medical science and technology industrial city with Pingshan biomedical industry cluster development main park as the core.

   In the future, Andrew T. Phillis hopes that more enterprises will come to Pingshan for development, and more basic research and industry-university-research-collaboration projects can be conducted in Pingshan. For the whole industry trend, he predicts that the application of AI will further improve the success rate of experiments and play an essential role in the R&D of new medicines, especially in the clinical trials of the medicines.